...
首页> 外文期刊>Pharmaceutical Methods >Formulation, Optimization and Characterization of Solid Dispersion of Glibenclamide
【24h】

Formulation, Optimization and Characterization of Solid Dispersion of Glibenclamide

机译:格列本脲固体分散体的配制,优化和表征

获取原文

摘要

Aim: The aim of the present study was to increase the solubility and dissolutionof Glibenclamide. Materials and Methods: Various batches ofsolid dispersion of Glibenclamide using water soluble carriers such asPEG (PEG 4000 and PEG 1500), were prepared as per the design expert(8.0.5) to optimize the drug release profile using response surfacemethodology (Face centered central composite design). Results: DSCand FTIR were used to characterize the solid dispersions. No chemicalinteraction was found between Glibenclamide and polymers. F3 and F13was found to be optimized batch according to the Face centered centralcomposite design (FCCCD). Conclusion: Drug release was directly proportionalto the concentration of polymer used for the formulation of soliddispersion. Thus, Glibenclamide with PEG 4000 and PEG 1500 had fasterdissolution rate than Glibenclamide itself.
机译:目的:本研究的目的是增加格列本脲的溶解度和溶解度。材料和方法:按照设计专家(8.0.5)的要求,使用水溶性载体(如PEG 4000和PEG 1500)制备了不同批次的格列本脲固体分散体,以使用响应表面方法(面心中心复合材料)优化药物释放曲线。设计)。结果:DSC和FTIR用于表征固体分散体。在格列本脲和聚合物之间未发现化学相互作用。根据面心中央复合设计(FCCCD),发现F3和F13是优化的批次。结论:药物释放与用于固体分散体的聚合物浓度成正比。因此,具有PEG 4000和PEG 1500的格列本脲比格列本脲本身具有更快的溶解速率。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号